应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
MRTX Mirati Therapeutics Inc.
停牌 04-23 07:34:09 EDT
58.70
+0.00
0.00%
最高
58.70
最低
58.70
成交量
0.00
今开
58.70
昨收
58.70
日振幅
0.00%
总市值
41.18亿
流通市值
22.84亿
总股本
7,015万
成交额
12.32亿
换手率
0.00%
流通股本
3,891万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
更新版 1-美国 FDA 拒绝批准安进公司肺癌药物 Lumakras 全面上市
Reuters · 2023-12-26
更新版 1-美国 FDA 拒绝批准安进公司肺癌药物 Lumakras 全面上市
加载更多
公司概况
公司名称:
Mirati Therapeutics Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Mirati Therapeutics,Inc.于2013年4月29日根据特拉华州法律注册成立,是一家临床阶段的生物制药公司,致力于开发针对性的肿瘤产品管道。公司将其发展计划的重点放在用于治疗特定亚群的癌症患者的药物,满足其需求。该公司的管道由三个候选产品: MGCD265 , MGCD516和mocetinostat 。MGCD265和MGCD516是口服生物型药物,是目前正在开发阶段的多靶点激酶抑制剂,治疗非小细胞肺癌、头颈部鳞状细胞癌和其他实体瘤患者。MGCD265目前处于1/2期临床开发阶段,MGCD516处于先进的临床前开发阶段,其临床第一阶段预计将在2014年上半年开始。 Mocetinostat是口服生物型药物,是光谱选择性组蛋白去乙酰化酶,这种抑制剂可以治疗第一线骨髓增生异常综合征 。该公司正计划到2014年底发起mocetinostat的第3阶段临床试验。此外,它会引发两个临床研究患者的淋巴瘤或实体肿瘤,在临床前模型中发现其肿瘤发生基因改变,肿瘤细胞对mocetinostat表现出更强的敏感性。
发行价格:
--
{"stockData":{"symbol":"MRTX","market":"US","secType":"STK","nameCN":"Mirati Therapeutics Inc.","latestPrice":58.7,"timestamp":1705957200000,"preClose":58.7,"halted":3,"volume":0,"delay":0,"floatShares":38905236,"shares":70147706,"eps":-12.151298,"marketStatus":"停牌","marketStatusCode":1,"change":0,"latestTime":"04-23 07:34:09 EDT","open":58.7,"high":58.7,"low":58.7,"amount":1232151297.83034,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-12.151298,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713879000000},"adr":0,"listingDate":1373860800000,"adjPreClose":58.7,"adrRate":0,"volumeRatio":0},"requestUrl":"/m/hq/s/MRTX?invite=TIGER026","defaultTab":"news","newsList":[{"id":"2394724100","title":"更新版 1-美国 FDA 拒绝批准安进公司肺癌药物 Lumakras 全面上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2394724100","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2394724100?lang=zh_cn&edition=full","pubTime":"2023-12-26 22:10","pubTimestamp":1703599802,"startTime":"0","endTime":"0","summary":" 路透12月26日 - 美国食品和药物管理局周二拒绝批准安进公司 的Lumakras用于治疗特定基因突变的肺癌患者,但没有撤销该药现有的加速审批资格。Lumakras于2021年在加速途径下获得FDA批准 ,确认数据是获得传统批准的一个条件。该公司表示,其较早的确证研究显示,与化疗相比,Lumakras可将晚期肺癌患者的疾病进展风险降低34%,但在总生存期方面没有明显差异。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://mirati.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0.0632},{"period":"1year","weight":0.377},{"period":"ytd","weight":-0.0009}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0412},{"period":"3month","weight":0.0306},{"period":"6month","weight":0.1968},{"period":"1year","weight":0.2123},{"period":"ytd","weight":0.0514}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Mirati Therapeutics,Inc.于2013年4月29日根据特拉华州法律注册成立,是一家临床阶段的生物制药公司,致力于开发针对性的肿瘤产品管道。公司将其发展计划的重点放在用于治疗特定亚群的癌症患者的药物,满足其需求。该公司的管道由三个候选产品: MGCD265 , MGCD516和mocetinostat 。MGCD265和MGCD516是口服生物型药物,是目前正在开发阶段的多靶点激酶抑制剂,治疗非小细胞肺癌、头颈部鳞状细胞癌和其他实体瘤患者。MGCD265目前处于1/2期临床开发阶段,MGCD516处于先进的临床前开发阶段,其临床第一阶段预计将在2014年上半年开始。 Mocetinostat是口服生物型药物,是光谱选择性组蛋白去乙酰化酶,这种抑制剂可以治疗第一线骨髓增生异常综合征 。该公司正计划到2014年底发起mocetinostat的第3阶段临床试验。此外,它会引发两个临床研究患者的淋巴瘤或实体肿瘤,在临床前模型中发现其肿瘤发生基因改变,肿瘤细胞对mocetinostat表现出更强的敏感性。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.064017},{"month":2,"riseRate":0.6,"avgChangeRate":0.013938},{"month":3,"riseRate":0.4,"avgChangeRate":-0.043956},{"month":4,"riseRate":0.3,"avgChangeRate":-0.038625},{"month":5,"riseRate":0.5,"avgChangeRate":0.005454},{"month":6,"riseRate":0.6,"avgChangeRate":0.09365},{"month":7,"riseRate":0.4,"avgChangeRate":0.01605},{"month":8,"riseRate":0.636364,"avgChangeRate":0.060453},{"month":9,"riseRate":0.636364,"avgChangeRate":0.226244},{"month":10,"riseRate":0.636364,"avgChangeRate":0.054028},{"month":11,"riseRate":0.727273,"avgChangeRate":0.056911},{"month":12,"riseRate":0.545455,"avgChangeRate":-0.006213}],"exchange":"NASDAQ","name":"Mirati Therapeutics Inc.","nameEN":"Mirati Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mirati Therapeutics Inc.(MRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Mirati Therapeutics Inc.(MRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Mirati Therapeutics Inc.,MRTX,Mirati Therapeutics Inc.股票,Mirati Therapeutics Inc.股票老虎,Mirati Therapeutics Inc.股票老虎国际,Mirati Therapeutics Inc.行情,Mirati Therapeutics Inc.股票行情,Mirati Therapeutics Inc.股价,Mirati Therapeutics Inc.股市,Mirati Therapeutics Inc.股票价格,Mirati Therapeutics Inc.股票交易,Mirati Therapeutics Inc.股票购买,Mirati Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mirati Therapeutics Inc.(MRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Mirati Therapeutics Inc.(MRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}